Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

DRUG REGISTRATION APPROVAL OF AMEILE IN FIRST LINE LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER

The board of directors (the "**Board**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**" and together with its subsidiaries, the "**Group**") is pleased to announce that "aumolertinib mesylate tablets" (product name "**AMEILE**" (阿美樂®)), a Category 1.1 innovative drug researched and developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.* (江蘇豪森藥業集團有限公司), a subsidiary of the Company, has been granted drug registration approval by the National Medical Products Administration of the People's Republic of China ("**NMPA**") for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("**NSCLC**") whose tumors have epidermal growth factor receptor ("**EGFR**") exon 19 deletions or exon 21 (L858R) mutations. This is the second indication of AMEILE which has been approved.

The drug registration approval of such new indication of AMEILE will further enrich and strengthen the oncology pipeline of the Group.

About AMEILE (aumolertinib mesylate tablets, HS-10296)

AMEILE is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor ("**EGFR-TKI**") with favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations. AMEILE has been approved by NPMA in March 2020 of its first indication which is for the treatment of adult patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC who have progressed on or after prior EGFR-TKI therapy. The said approval is the second indication of AMEILE which is for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, December 16, 2021

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*